A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)

Purpose

The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called diltiazem.

Condition

  • Healthy

Eligibility

Eligible Ages
Between 18 Years and 55 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Be in good health - BMI between 18.5 and 32 kg/m2, inclusive

Exclusion Criteria

  • History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological (history of a bleeding disorder, abnormal bleeding or a hereditary or acquired coagulation or platelet disorder), hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke, intercranial hemorrhage, and chronic seizures) abnormalities or diseases - History of cancer (malignancy)

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Basic Science
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Period 1: Nemtabrutinib 		Participants will receive nemtabrutinib followed by a protocol specified wash-out period.
  • Drug: Nemtabrutinib
    Oral administration
    Other names:
    • MK-1026
Experimental
Period 2: Diltiazem + Nemtabrutinib 		Participants will receive diltiazem plus nemtabrutinib.
  • Drug: Nemtabrutinib
    Oral administration
    Other names:
    • MK-1026
  • Drug: Diltiazem
    Oral administration

Recruiting Locations

Fortea CRU Madison (0001)
Madison 5261457, Wisconsin 5279468 53704
Contact:
Taha El-Shahat
608-241-7285
taha.elshahat@fortrea.com

More Details

Status
Recruiting
Sponsor
Merck Sharp & Dohme LLC

Study Contact

Toll Free Number
1-888-577-8839
Trialsites@msd.com